Payment overview · 2025
General Payments
$399.78
14 reported records · 8 companies
Healthcare provider profile · identity verified
Dona E Cooper-Dockery, MD
Allopathic & Osteopathic Physicians|Internal Medicine · MCALLEN, TX · NPI 1003093147
Verified facts
What the public records show
CMS Open Payments records show Dona E Cooper-Dockery, MD received $399.78 in general payments during 2025 across 14 reported records.
ADC THERAPEUTICS AMERICA, INC. accounted for 30.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Linzess, Mounjaro, Paxlovid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Vraylar by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 214 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 148 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 272 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ADC THERAPEUTICS AMERICA, INC. | Unresolved — no canonical attribution shown | $121.36 | 30.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $99.93 | 25.0% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $38.07 | 9.5% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $36.86 | 9.2% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $31.95 | 8.0% | 2 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $30.82 | 7.7% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.88 | 5.5% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.91 | 4.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $399.78 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZYNLONTA Normalized: zynlonta |
Drug | ADC THERAPEUTICS AMERICA, INC. | $121.36 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $99.93 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $77.16 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $36.86 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $31.95 | 2 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $30.82 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $22.77 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $21.88 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $21.20 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $21.20 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.91 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $18.91 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $16.87 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 106 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 105 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 148 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 29 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
105 | 48 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
214 | 66 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
148 | 43 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
70 | 27 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
272 | 84 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
106 | 36 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
29 | 27 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1012 | 381 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 577 | 208 |
| Metformin Hcl | Metformin Hcl | 465 | 164 |
| Losartan Potassium | Losartan Potassium | 431 | 153 |
| Levothyroxine Sodium | Levothyroxine Sodium | 402 | 153 |
| Lisinopril | Lisinopril | 367 | 127 |
| Metoprolol Succinate | Metoprolol Succinate | 360 | 150 |
| Gabapentin | Gabapentin | 331 | 127 |
| Amlodipine Besylate | Amlodipine Besylate | 318 | 128 |
| Ozempic | Semaglutide | 272 | 84 |
| Pantoprazole Sodium | Pantoprazole Sodium | 264 | 112 |
| Omeprazole | Omeprazole | 257 | 109 |
| Tramadol Hcl | Tramadol Hcl | 248 | 68 |
| Alendronate Sodium | Alendronate Sodium | 233 | 92 |
| Tamsulosin Hcl | Tamsulosin Hcl | 231 | 90 |
| Furosemide | Furosemide | 219 | 82 |
| Jardiance | Empagliflozin | 214 | 66 |
| Alprazolam | Alprazolam | 197 | 53 |
| Trazodone Hcl | Trazodone Hcl | 185 | 48 |
| Escitalopram Oxalate | Escitalopram Oxalate | 166 | 54 |
| Clopidogrel | Clopidogrel Bisulfate | 162 | 67 |
| Montelukast Sodium | Montelukast Sodium | 160 | 61 |
| Meloxicam | Meloxicam | 159 | 81 |
| Famotidine | Famotidine | 155 | 79 |
| Fluticasone Propionate | Fluticasone Propionate | 153 | 87 |
| Januvia | Sitagliptin Phosphate | 151 | 52 |
| Hydralazine Hcl | Hydralazine Hcl | 150 | 66 |
| Mounjaro | Tirzepatide | 148 | 43 |
| Valsartan | Valsartan | 147 | 62 |
| Simvastatin | Simvastatin | 138 | 44 |
| Diclofenac Sodium | Diclofenac Sodium | 134 | 75 |
| Farxiga | Dapagliflozin Propanediol | 134 | 55 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 126 | 47 |
| Azithromycin | Azithromycin | 125 | 109 |
| Irbesartan | Irbesartan | 122 | 53 |
| Zolpidem Tartrate | Zolpidem Tartrate | 121 | 26 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 119 | 62 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 118 | 36 |
| Nifedipine Er | Nifedipine | 114 | 37 |
| Glipizide | Glipizide | 113 | 48 |
| Eliquis | Apixaban | 106 | 36 |
| Linzess | Linaclotide | 105 | 48 |
| Hydrochlorothiazide | Hydrochlorothiazide | 103 | 45 |
| Carvedilol | Carvedilol | 100 | 38 |
| Donepezil Hcl | Donepezil Hcl | 96 | 44 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 94 | 48 |
| Metoprolol Tartrate | Metoprolol Tartrate | 94 | 42 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 90 | 35 |
| Ibuprofen | Ibuprofen | 89 | 64 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 84 | 25 |
| Pravastatin Sodium | Pravastatin Sodium | 80 | 34 |
| Pregabalin | Pregabalin | 79 | 24 |
| Baclofen | Baclofen | 77 | 40 |
| Duloxetine Hcl | Duloxetine Hcl | 75 | 33 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 75 | 37 |
| Myrbetriq | Mirabegron | 74 | 34 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 73 | 29 |
| Clonazepam | Clonazepam | 72 | 19 |
| Ezetimibe | Ezetimibe | 71 | 28 |
| Sertraline Hcl | Sertraline Hcl | 71 | 37 |
| Trulicity | Dulaglutide | 70 | 27 |
| Potassium Chloride | Potassium Chloride | 69 | 27 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 68 | 25 |
| Quetiapine Fumarate | Quetiapine Fumarate | 67 | 22 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 65 | 26 |
| Mupirocin | Mupirocin | 64 | 40 |
| Citalopram Hbr | Citalopram Hydrobromide | 63 | 21 |
| Fluconazole | Fluconazole | 63 | 55 |
| Meclizine Hcl | Meclizine Hcl | 63 | 37 |
| Nabumetone | Nabumetone | 60 | 31 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 59 | 26 |
| Glimepiride | Glimepiride | 58 | 18 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 56 | 17 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 55 | 28 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 54 | 27 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 53 | 22 |
| Prednisone | Prednisone | 53 | 45 |
| Fenofibrate | Fenofibrate Nanocrystallized | 52 | 21 |
| Tizanidine Hcl | Tizanidine Hcl | 52 | 32 |
| Lactulose | Lactulose | 51 | 15 |
| Kerendia | Finerenone | 50 | 17 |
| Celecoxib | Celecoxib | 49 | 22 |
| Memantine Hcl | Memantine Hcl | 47 | 20 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 47 | 29 |
| Dicyclomine Hcl | Dicyclomine Hcl | 46 | 29 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 46 | 25 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 45 | 29 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 44 | 18 |
| Pioglitazone Hcl | Pioglitazone Hcl | 44 | 17 |
| Enalapril Maleate | Enalapril Maleate | 42 | 15 |
| Finasteride | Finasteride | 42 | 18 |
| Naproxen | Naproxen | 41 | 22 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 40 | 14 |
| Cilostazol | Cilostazol | 40 | 12 |
| Lorazepam | Lorazepam | 40 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 40 | 11 |
| Spironolactone | Spironolactone | 40 | 19 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 38 | 13 |
| Nystatin | Nystatin | 38 | 22 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 36 | 19 |
| Tradjenta | Linagliptin | 35 | 14 |
| Azelastine Hcl | Azelastine Hcl | 34 | 18 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 34 | 30 |
| Vascepa | Icosapent Ethyl | 34 | 15 |
| Atenolol | Atenolol | 33 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 33 | 33 |
| Allopurinol | Allopurinol | 32 | 17 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 32 | 28 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 32 | 17 |
| Levetiracetam | Levetiracetam | 32 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 32 | 26 |
| Bumetanide | Bumetanide | 31 | 15 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 31 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 31 | 11 |
| Clonidine Hcl | Clonidine Hcl | 30 | 16 |
| Hydrocortisone | Hydrocortisone | 30 | 30 |
| Glyburide | Glyburide | 29 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 29 | 27 |
| Amitriptyline Hcl | Amitriptyline Hcl | 28 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 28 | suppressed |
| Glipizide Er | Glipizide | 28 | suppressed |
| Lovastatin | Lovastatin | 27 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 26 | 14 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 26 | 11 |
| Olanzapine | Olanzapine | 26 | suppressed |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 25 | 16 |
| Solifenacin Succinate | Solifenacin Succinate | 25 | suppressed |
| Clotrimazole | Clotrimazole | 24 | 15 |
| Labetalol Hcl | Labetalol Hcl | 24 | suppressed |
| Telmisartan | Telmisartan | 24 | 13 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 23 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 23 | 19 |
| Rybelsus | Semaglutide | 23 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | 12 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 21 |
| Doxazosin Mesylate | Doxazosin Mesylate | 21 | suppressed |
| Lamotrigine | Lamotrigine | 21 | suppressed |
| Prolia | Denosumab | 21 | 16 |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 20 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 20 | 12 |
| Buspirone Hcl | Buspirone Hcl | 20 | 11 |
| Latanoprost | Latanoprost | 20 | suppressed |
| Sucralfate | Sucralfate | 20 | 13 |
| Bupropion Xl | Bupropion Hcl | 19 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 19 | 12 |
| Dutasteride | Dutasteride | 19 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 19 | suppressed |
| Ketoconazole | Ketoconazole | 19 | 12 |
| Metronidazole | Metronidazole | 19 | 18 |
| Silver Sulfadiazine | Silver Sulfadiazine | 19 | suppressed |
| Synthroid | Levothyroxine Sodium | 19 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 18 | suppressed |
| Loperamide | Loperamide Hcl | 18 | 11 |
| Metformin Hcl Er | Metformin Hcl | 18 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 18 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 18 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 17 | suppressed |
| Levemir Flexpen | Insulin Detemir | 17 | suppressed |
| Lidocaine | Lidocaine | 17 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 17 | suppressed |
| Ofloxacin | Ofloxacin | 17 | 15 |
| Ondansetron Odt | Ondansetron | 17 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 17 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 16 | 12 |
| Methylprednisolone | Methylprednisolone | 15 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 15 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 14 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 14 | suppressed |
| Mirtazapine | Mirtazapine | 14 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 14 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 14 | suppressed |
| Clonidine | Clonidine | 13 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 13 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Rivastigmine | Rivastigmine | 13 | suppressed |
| Ssd | Silver Sulfadiazine | 13 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 13 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Xifaxan | Rifaximin | 13 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 12 | suppressed |
| Vraylar | Cariprazine Hcl | 12 | suppressed |
| Carvedilol Er | Carvedilol Phosphate | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | 11 |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Humulin R U-500 Kwikpen | Insulin Regular, Human | 11 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 11 | 11 |
| Ranolazine Er | Ranolazine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $399.78 · 14 records | ADC THERAPEUTICS AMERICA, INC. | CREON, Dexcom G6 Transmitter, ELIQUIS, LINZESS, MOUNJARO, NURTEC ODT, PAXLOVID, UBRELVY, UZEDY, VOQUEZNA, Wegovy, ZEPBOUND, ZYNLONTA | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error